A5011644667- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Breast Lesions and Carcinomas
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Estrogen and related hormone effects
- PI3K/AKT/mTOR signaling in cancer
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Cancer Diagnosis and Treatment
- DNA Repair Mechanisms
- Cancer, Hypoxia, and Metabolism
- Metastasis and carcinoma case studies
- Lung Cancer Treatments and Mutations
- Angiogenesis and VEGF in Cancer
- RNA modifications and cancer
- MRI in cancer diagnosis
- BRCA gene mutations in cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer Research and Treatments
- Wnt/β-catenin signaling in development and cancer
National Hospital Organization Kyushu Cancer Center
2016-2025
Ludwig-Maximilians-Universität München
2024
Memorial Sloan Kettering Cancer Center
2024
Harbin Medical University
2024
Institut Jules Bordet
2024
Université de Versailles Saint-Quentin-en-Yvelines
2024
Université Paris-Saclay
2024
Cornell University
2024
Kyushu University
2010-2023
Eli Lilly (United States)
2019
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and cytotoxic topoisomerase I inhibitor. In phase 1 dose-finding study, majority the patients with advanced HER2-positive breast cancer had response to trastuzumab (median duration, 20.7 months). The efficacy in metastatic previously treated emtansine requires confirmation.In this two-part, open-label, single-group,...
AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of inhibitor capivasertib, as an addition to fulvestrant therapy, patients with hormone receptor-positive advanced breast cancer are limited.
Abstract Background Recurrence occurs in a variety of forms and different organs after ‘curative resection’ gastric cancer. This study investigated the postoperative prognosis for each type recurrence. Methods From 1969 to 1988, 939 patients with cancer underwent curative resection; data on 130 207 who died recurrence were analysed. Attention was focused site outcome. Results Haematogenous evident 54 per cent (70 patients), peritoneal 43 (56 130), lymph node 12 (16 130) local 22 (29 130)....
Topochemical synthesis of gold nanoparticles (AuNPs) was achieved on crystalline cellulose single nanofibers (CSNFs), which were tailored from native cellulose. Exposed AuNPs@CSNFs composite exhibited an excellent catalytic efficiency: the turnover frequency up to 840 times that conventional polymer-supported AuNPs, for a model aqueous reduction reaction. Our novel strategy provides promising solution realize efficient use limited noble metals using natural bioresources.
Akt/PKB is a serine/threonine kinase that plays an important role in survival when cells are exposed to different apoptotic stimuli. Aberrant activation of breast carcinoma associated with poor prognosis and resistance endocrine therapy chemotherapy. The Akt signaling pathway currently attracts considerable attention as new target for effective therapeutic strategies. We therefore investigated the relationship between clinicopathologic variables including hormone receptor HER2/neu status....
Growth factor receptor-mediated signal transduction has been implicated in conferring resistance to conventional chemotherapy on cancer cells. We describe a pathway that involves AKT/PI3K mediate chemoresistance gastric patients. Primary carcinoma tissues and corresponding normal mucosa were obtained from 76 patients who underwent surgery the Department of Surgery II Kyushu University Hospital years 1996-2000. AKT activation was investigated by immunostaining with phosphorylation-specific...
Abstract Background Trastuzumab deruxtecan (T-DXd, DS-8201) is an antibody-drug conjugate with a HER2 antibody, tetrapeptide-based cleavable linker, and novel topoisomerase I inhibitor payload. DESTINY-Breast01 (NCT03248492) open-label, international, multicenter, phase 2 study of T-DXd in patients positive metastatic breast cancer (MBC) supported regulatory approval the US Japan. Updated longer-term safety efficacy results are presented here. Methods All were required to have MBC that...
Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth factor receptor 2 (HER2)-negative [immunohistochemistry (IHC) 0, 1+, or 2+/in situ hybridization (ISH) negative]; approximately 60% BCs traditionally HER2-negative express low levels HER2. HER2-low (IHC 1+ IHC 2+/ISH-) status became clinically actionable with approval trastuzumab deruxtecan to treat unresectable/metastatic BC. Greater understanding patients disease is urgently needed.This...
BackgroundImlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations the gene encoding ERα (ESR1).MethodsIn phase 3, open-label trial, we enrolled patients ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer recurred or progressed during after aromatase inhibitor therapy, administered alone cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor....
Background: Despite advances in the treatment of early triple-negative breast cancer (TNBC), patients with residual invasive disease after neoadjuvant therapy have a high risk recurrence and worse survival outcomes than those who pathological complete response (pCR). Improving TNBC remains an unmet need requiring new adjuvant approaches. Datopotamab deruxtecan (Dato-DXd) is antibody–drug conjugate comprising humanized anti-trophoblast cell-surface antigen 2 immunoglobulin G1 (IgG1)...
The mta1 gene is a recently identified novel candidate metastasis-associated gene. deduced amino acid sequence contains an src homology-3 domain binding motif, zinc finger motif and possible phosphorylation sites, suggesting that this involved in signal transduction or regulation of expression. purpose our study was to examine the mRNA expression levels MTA1, human homologue rat colorectal gastric carcinomas thus evaluate relevance carcinoma progression. MTA1 36 34 samples compared with...
A new femtosecond time-resolved interferometer was developed that utilizes interference fringes in the frequency domain to obtain simultaneously difference phase spectra (DPS) and transmission with a multichannel spectrometer. For first time our knowledge, transient oscillations were observed DPS spectral shift of probe pulse resolved together rise DPS, which is clear evidence for induced modulation absorptive materials.
The molecular mechanisms underlying endotoxin-induced insulin resistance remain unclear. Endotoxin or lipopolysaccharide (LPS) injection is a potent stimulator of inducible nitric oxide synthase (iNOS). This study in rats, using the specific iNOS inhibitor aminoguanidine, investigated role hyperglycemia and resistance. LPS led to hyperglycemia, resistance, increased protein expression activity. Aminoguanidine prevented LPS-induced without affecting levels expression. attenuated reflected by...
Purpose: To retrospectively evaluate the magnetic resonance (MR) imaging findings of phyllodes tumor breast and to compare these with histologic grade. Materials Methods: Institutional review board approval informed consent were obtained. The authors reviewed MR in 30 female patients aged 16–73 years (mean, 40.2 years) surgically confirmed tumors. Analyzed included shape, margin, internal enhancement, size; signal intensity (SI) higher than that normal tissue on T1-weighted images; SI lower...